Low-grade serous ovarian cancer: Expert consensus report on the state of the science

Rachel N. Grisham; Brian M. Slomovitz; Nicole Andrews; Susana Banerjee; Jubilee Brown; Mark S. Carey; Herman Chui; Robert L. Coleman; Amanda N. Fader; Stephanie Gaillard; Charlie Gourley; Anil K. Sood; Bradley J. Monk; Kathleen N. Moore; Isabelle Ray-Coquard; Ie Ming Shih; Shannon N. Westin; Kwong Kwok Wong; David M. Gershenson

doi:10.1136/ijgc-2023-004610

Low-grade serous ovarian cancer: Expert consensus report on the state of the science

Rachel N. Grisham, Brian M. Slomovitz, Nicole Andrews, Susana Banerjee, Jubilee Brown, Mark S. Carey, Herman Chui, Robert L. Coleman, Amanda N. Fader, Stephanie Gaillard, Charlie Gourley, Anil K. Sood, Bradley J. Monk, Kathleen N. Moore, Isabelle Ray-Coquard, Ie Ming Shih, Shannon N. Westin, Kwong Kwok Wong, David M. Gershenson

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel - presented in this consensus document - will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.

Original language	English (US)
Pages (from-to)	1331-1344
Number of pages	14
Journal	International Journal of Gynecological Cancer
Volume	33
Issue number	9
DOIs	https://doi.org/10.1136/ijgc-2023-004610
State	Published - Sep 1 2023

Keywords

Cystadenocarcinoma, Serous
Ovarian Cancer
Pathology

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1136/ijgc-2023-004610

Cite this

Grisham, R. N., Slomovitz, B. M., Andrews, N., Banerjee, S., Brown, J., Carey, M. S., Chui, H., Coleman, R. L., Fader, A. N., Gaillard, S., Gourley, C., Sood, A. K., Monk, B. J., Moore, K. N., Ray-Coquard, I., Shih, I. M., Westin, S. N., Wong, K. K., & Gershenson, D. M. (2023). Low-grade serous ovarian cancer: Expert consensus report on the state of the science. International Journal of Gynecological Cancer, 33(9), 1331-1344. https://doi.org/10.1136/ijgc-2023-004610

Grisham, RN, Slomovitz, BM, Andrews, N, Banerjee, S, Brown, J, Carey, MS, Chui, H, Coleman, RL, Fader, AN, Gaillard, S, Gourley, C, Sood, AK, Monk, BJ, Moore, KN, Ray-Coquard, I, Shih, IM, Westin, SN , Wong, KK & Gershenson, DM 2023, 'Low-grade serous ovarian cancer: Expert consensus report on the state of the science', International Journal of Gynecological Cancer, vol. 33, no. 9, pp. 1331-1344. https://doi.org/10.1136/ijgc-2023-004610

@article{b6685e48f7954e25a558fd0143744936,

title = "Low-grade serous ovarian cancer: Expert consensus report on the state of the science",

abstract = "Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel - presented in this consensus document - will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.",

keywords = "Cystadenocarcinoma, Serous, Ovarian Cancer, Pathology",

author = "Grisham, {Rachel N.} and Slomovitz, {Brian M.} and Nicole Andrews and Susana Banerjee and Jubilee Brown and Carey, {Mark S.} and Herman Chui and Coleman, {Robert L.} and Fader, {Amanda N.} and Stephanie Gaillard and Charlie Gourley and Sood, {Anil K.} and Monk, {Bradley J.} and Moore, {Kathleen N.} and Isabelle Ray-Coquard and Shih, {Ie Ming} and Westin, {Shannon N.} and Wong, {Kwong Kwok} and Gershenson, {David M.}",

note = "Publisher Copyright: {\textcopyright} IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.",

year = "2023",

month = sep,

day = "1",

doi = "10.1136/ijgc-2023-004610",

language = "English (US)",

volume = "33",

pages = "1331--1344",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Wolters Kluwer Health",

number = "9",

}

TY - JOUR

T1 - Low-grade serous ovarian cancer

T2 - Expert consensus report on the state of the science

AU - Grisham, Rachel N.

AU - Slomovitz, Brian M.

AU - Andrews, Nicole

AU - Banerjee, Susana

AU - Brown, Jubilee

AU - Carey, Mark S.

AU - Chui, Herman

AU - Coleman, Robert L.

AU - Fader, Amanda N.

AU - Gaillard, Stephanie

AU - Gourley, Charlie

AU - Sood, Anil K.

AU - Monk, Bradley J.

AU - Moore, Kathleen N.

AU - Ray-Coquard, Isabelle

AU - Shih, Ie Ming

AU - Westin, Shannon N.

AU - Wong, Kwong Kwok

AU - Gershenson, David M.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel - presented in this consensus document - will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.

AB - Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel - presented in this consensus document - will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.

KW - Cystadenocarcinoma, Serous

KW - Ovarian Cancer

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=85168664983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168664983&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2023-004610

DO - 10.1136/ijgc-2023-004610

M3 - Article

C2 - 37591609

AN - SCOPUS:85168664983

SN - 1048-891X

VL - 33

SP - 1331

EP - 1344

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 9

ER -

Low-grade serous ovarian cancer: Expert consensus report on the state of the science

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this